IL290716A - A method of treating hiv with cabotgeravir and rilfivirin - Google Patents

A method of treating hiv with cabotgeravir and rilfivirin

Info

Publication number
IL290716A
IL290716A IL290716A IL29071622A IL290716A IL 290716 A IL290716 A IL 290716A IL 290716 A IL290716 A IL 290716A IL 29071622 A IL29071622 A IL 29071622A IL 290716 A IL290716 A IL 290716A
Authority
IL
Israel
Prior art keywords
cabotegravir
rilpivirine
treating hiv
hiv
treating
Prior art date
Application number
IL290716A
Other languages
English (en)
Hebrew (he)
Original Assignee
Viiv Healthcare Co
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co, Janssen Sciences Ireland Unlimited Co filed Critical Viiv Healthcare Co
Publication of IL290716A publication Critical patent/IL290716A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL290716A 2019-10-01 2022-02-17 A method of treating hiv with cabotgeravir and rilfivirin IL290716A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962908995P 2019-10-01 2019-10-01
US201962908882P 2019-10-01 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US202063052214P 2020-07-15 2020-07-15
PCT/IB2020/059185 WO2021064618A1 (en) 2019-10-01 2020-10-01 Method for treating hiv with cabotegravir and rilpivirine

Publications (1)

Publication Number Publication Date
IL290716A true IL290716A (en) 2022-04-01

Family

ID=72826936

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290716A IL290716A (en) 2019-10-01 2022-02-17 A method of treating hiv with cabotgeravir and rilfivirin

Country Status (11)

Country Link
US (3) US20220347174A1 (enExample)
EP (1) EP4037661A1 (enExample)
JP (1) JP7791083B2 (enExample)
KR (1) KR20220074880A (enExample)
CN (2) CN114502166A (enExample)
AU (1) AU2020358156B2 (enExample)
CA (1) CA3155587A1 (enExample)
CL (1) CL2022000790A1 (enExample)
IL (1) IL290716A (enExample)
MX (1) MX2022003945A (enExample)
WO (1) WO2021064618A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
TW202408526A (zh) * 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
KR101811314B1 (ko) * 2009-09-22 2017-12-26 얀센 알 앤드 디 아일랜드 Hiv 감염의 치료 및 예방
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
CN104902905A (zh) 2012-12-14 2015-09-09 葛兰素史克有限责任公司 药物组合物
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EA201790495A1 (ru) 2014-09-26 2017-09-29 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Фармацевтические композиции длительного действия
WO2019016732A1 (en) * 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物
EP3986561B1 (en) * 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
JP7791083B2 (ja) 2025-12-23
CL2022000790A1 (es) 2022-11-25
AU2020358156B2 (en) 2024-06-06
EP4037661A1 (en) 2022-08-10
CN118416069A (zh) 2024-08-02
WO2021064618A1 (en) 2021-04-08
JP2022550828A (ja) 2022-12-05
US12636285B2 (en) 2026-05-26
US12636286B2 (en) 2026-05-26
CN114502166A (zh) 2022-05-13
US20220347174A1 (en) 2022-11-03
CA3155587A1 (en) 2021-04-08
AU2020358156A1 (en) 2022-04-21
US20250302829A1 (en) 2025-10-02
US20250302830A1 (en) 2025-10-02
MX2022003945A (es) 2022-04-25
KR20220074880A (ko) 2022-06-03

Similar Documents

Publication Publication Date Title
IL266454B (en) Implant and method of creating the implant
EP3321388A4 (en) Grain-oriented electromagnetic steel sheet and method for manufacturing same
EP3205738A4 (en) Low-core-loss grain-oriented electromagnetic steel sheet and method for manufacturing same
PL3272894T3 (pl) Blacha cienka z niezorientowanej stali elektrotechnicznej oraz sposób jej wytwarzania
SG11202003854WA (en) Surface-treated steel sheet and method for manufacturing the same
ZA202000837B (en) Metal sheet treatment method and metal sheet treated with this method
EP3675813A4 (en) METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS
ZA202101342B (en) Compositions and methods for treating the eye
PL3893827T3 (pl) Ochraniacz inkontynencyjny dla mężczyzn, zestaw i sposób
IL271987A (en) Regimens for the treatment of HIV infections and AIDS
SG11202005101PA (en) High-mn steel and method for manufacturing same
HUE066514T2 (hu) Fémlemezkezelési eljárás és ezzel az eljárással kezelt fémlemez
ZA202101360B (en) Compositions and methods for treating the eye
ZA202007183B (en) Compositions and methods for treating the eye
GB2618437B (en) Vehicle and method
ZA202106010B (en) Hybrid boiler-dryer and method
GB201911141D0 (en) Materials and method
GB201817362D0 (en) Circuitry and method
GB201811899D0 (en) Article and method
GB2569974B (en) Controller and method
ZA202202977B (en) Metal sheet treatment method and metal sheet treated with this method
HK40079997A (en) Method for treating hiv with cabotegravir and rilpivirine
GB2583191B (en) Method and article
IL271180A (en) Methods for preventing and treating urinary incontinence
GB201911134D0 (en) Materials and method